Table 2 Results of the subgroup analysis
From: Prognostic value of microRNAs in patients with small cell lung cancer: a meta-analysis
Subgroup | HR | LL | UL | N | I2 | P | Heterogeneity between groups: p value |
|---|---|---|---|---|---|---|---|
Total | 1.25 | 1.06 | 1.47 | 15 | 89.7% | 0.000 | |
Influence | 0.000 | ||||||
Oncogenic | 1.60 | 1.35 | 1.60 | 9 | 92.1% | 0.000 | |
Tumor suppressive | 0.42 | 0.30 | 0.57 | 6 | 0.0% | 0.501 | |
Prognosis | 0.778 | ||||||
OS | 1.20 | 1.02 | 1.42 | 8 | 89.8% | 0.000 | |
PFS | 1.09 | 0.53 | 2.22 | 7 | 90.5% | 0.000 | |
Resources | 0.000 | ||||||
serum | 2.15 | 0.57 | 8.17 | 3 | 95.6% | 0.000 | |
plasma | 1.98 | 1.41 | 2.80 | 3 | 0.0% | 0.551 | |
tumor | 0.97 | 0.84 | 1.12 | 9 | 84.2% | 0.000 | |
miRNA Panel | 0.215 | ||||||
1 | 1.25 | 1.06 | 1.48 | 11 | 90.9% | 0.000 | |
2 | 0.64 | 0.14 | 3.00 | 3 | 90.8% | 0.000 | |
3 | 2.10 | 1.10 | 4.01 | 1 | 0.0% | . | |
Follow-up time | 0.056 | ||||||
<50 months | 1.84 | 0.97 | 3.46 | 8 | 87.8% | 0.000 | |
>50 months | 0.97 | 0.84 | 1.1290.8$ | 7 | 86.1% | 0.000 |